Shots:
- Beacon has reported the 12mos. data from P-II (DAWN) trial assessing laruparetigene zovaparvovec (laru-zova) in pts with XLRP who have previously been treated with an AAV vector-based gene therapy delivering the full-length RPGR protein
- Data showed sustained improvements in low luminance visual acuity (LLVA) & microperimetry mean sensitivity through Mos. 12, with 50% of high-dose pts achieving ≥2-line vision improvement & 25% achieving ≥3-line gains from baseline, while 67% of low-dose pts achieved ≥2-line gain; data were presented in ARVO’26
- Beacon is also evaluating some pts with LLVA improvement & changes in microperimetry mean macular sensitivity in the P-II/III (VISTA) trial of laru-zova for XLRP, with topline data expected in H2’26
Ref: Beacon| Image: Beacon | Press Release
Related News: Bayer Reports P-III (REVEAL) Trial Data on Iodine 124 evuzamitide to Diagnose Cardiac Amyloidosis
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
